LEMS in Lung Cancer Patient Given Tecentriq Shows Need for Vigilance

LEMS in Lung Cancer Patient Given Tecentriq Shows Need for Vigilance

313036

LEMS in Lung Cancer Patient Given Tecentriq Shows Need for Vigilance

The rare case of a man with advanced small cell lung cancer (SCLC) who went on to develop Lambert-Eaton myasthenic syndrome (LEMS) after receiving treatment with Tecentriq (atezolizumab), an immune checkpoint inhibitor, was described in a recent study. Researchers say this case highlights the need for vigilance in treating people with lung cancer with this type of immunotherapy. “Physicians need to be aware of the possibility of LEMS arising in SCLC patients receiving” treatments like…

You must be logged in to read/download the full post.